文献速递心脏核医学

基于冠状动脉疾病患病率的82铷PET心肌灌注显像诊断心肌缺血的成本效益分析

Cost-effectiveness of 82-Rubidium PET myocardial perfusion imaging for the diagnosis of myocardial ischemia depending on the prevalence of coronary artery disease.
PubMed 文献 · EJNMMI Res · 2023-02-08

基于RUBIS试验数据,从法国医疗体系视角、12个月时间 horizon,对疑诊心肌缺血患者比较82铷PET-MPI与Tc-SPECT-MPI的成本效益。在阻塞性冠状动脉疾病验前概率>15%的患者中,Rb-PET-MPI策略平均费用较SPECT-MPI低219欧元,增量成本效益比为负2730欧元,Rb-PET-MPI策略具有92%概率成为优势策略。

要点

  • Rb-PET-MPI策略平均费用较Tc-SPECT-MPI低219欧元(1192欧元 vs 973欧元,p<0.01)。
  • 在验前概率>15%患者中,增量成本效益比为负2730欧元/每增加一例准确诊断。
  • Rb-PET-MPI策略成为优势策略(省钱且改善结局)的概率为92%。

核心结论

  • 在阻塞性冠状动脉疾病验前概率>15%的疑诊心肌缺血患者中,Rb-PET-MPI相较于Tc-SPECT-MPI具有成本效益。

研究设计与样本

  • 基于RUBIS试验结果的经济学评价,从法国医疗体系视角、时间跨度为12个月,对所有患者计算1年内的成本与以诊断准确性为效果指标的效果,并进行增量分析,采用bootstrap法估计结果的不确定性。

主要发现

  • Rb-PET-MPI策略检测心肌缺血的1年平均费用较SPECT-MPI策略低219欧元(1192欧元(±1834) vs 973欧元(±1939),p<0.01)。
  • 在验前概率>15%的患者中,Rb-PET-MPI对比Tc-SPECT-MPI策略的1年增量成本效益比为负值:-2730欧元(每增加一例准确诊断所节省的费用)。
  • 成本与结局联合分布分析显示,Rb-PET-MPI策略具有92%的概率为优势策略(节省费用且改善结局)。

关键数值与推荐

  • 在阻塞性冠状动脉疾病验前概率>15%的患者中,Rb-PET-MPI策略的1年增量成本效益比为-2730欧元(每增加一例准确诊断所节省的费用)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: 82-Rubidium-Positron emission tomography myocardial perfusion imaging (Rb-PET-MPI) offers higher diagnostic performance for the detection of myocardial ischemia compared to Tc-SPECT-MPI. The aim of this economic evaluation was to perform a cost-effectiveness analysis of Rb-PET-MPI versus Tc-SPECT-MPI in patients with suspected myocardial ischemia according to pretest probabilities (PTP) of obstructive coronary artery disease based on the results of the RUBIS Trial. METHODS: Costs and effectiveness were calculated for all patients over 1 year and an incremental analysis of differences in costs and effectiveness in terms of diagnostic accuracy was performed. The uncertainty of the results was estimated using bootstrap. The analysis was conducted from the perspective of the French health care system with a time horizon of 12 months. RESULTS: The average cost of a Rb-PET-MPI-based strategy for the detection of myocardial ischemia was €219 lower than a SPECT-MPI-based strategy (€1192 (± 1834) vs €973 (± 1939), p < 0.01). The one-year incremental cost-effectiveness ratio was negative: - €2730 (money saved per additional accurate diagnosis) in patients presenting PTP > 15% for the Rb-PET-MPI vs. Tc-SPECT-MPI strategy. Analysis of the joint distribution of costs and outcomes found that the Rb-PET-MPI strategy had a 92% probability to be dominant (cost-saving and outcome-improving). CONCLUSIONS: Rb-PET-MPI is cost-effective compared to Tc-SPECT-MPI for the detection of myocardial ischemia in patients with PTP > 15% of obstructive coronary artery disease. TRIAL REGISTRATION: RUBIS Trial registration: NCT01679886, Registered 03 September 2012, https://clinicaltrials.gov/ct2/show/NCT01679886 .

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Mimouni M, Bulsei J, Darlington M, et al. Cost-effectiveness of 82-Rubidium PET myocardial perfusion imaging for the diagnosis of myocardial ischemia depending on the prevalence of coronary artery disease. EJNMMI Res. 2023. PMID: 36752899. doi:10.1186/s13550-023-00954-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。